远大医药:脓毒症创新疗法中国II期临床成功 核药领跑者持续强化先发优势

国信证券
Jun 13

事项:公司公告:1)创新药物STC3141 在中国开展的用于治疗脓毒症的II 期临床研究成功达到临床终点;2)创新RDC 产品TLX591 加入国际多中心III 期临床试验的申请已获国家药监局受理;3)用于诊断肝细胞癌的创新RDC GPN02006 在中国开展的研究者发起的临床研究(IIT 临床研究)结果将于2025 年北美核医学与分子影像学会(SNMMI)年会中公布;4)成都温江核药全球研发及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10